How have LIXT shares performed in 2024?

Lixte Biotechnology's stock was trading at $2.35 at the beginning of the year. Since then, LIXT shares have increased by 47.7% and is now trading at $3.47. View the best growth stocks for 2024 here .

When is Lixte Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our LIXT earnings forecast .

How were Lixte Biotechnology's earnings last quarter?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) released its earnings results on Tuesday, March, 19th. The company reported ($0.41) earnings per share for the quarter.

When did Lixte Biotechnology's stock split?

Shares of Lixte Biotechnology reverse split before market open on Monday, June 5th 2023. The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Lixte Biotechnology IPO?

Lixte Biotechnology (LIXT) raised $7 million in an initial public offering (IPO) on Wednesday, November 25th 2020. The company issued 1,500,000 shares at $4.75 per share. WestPark Capital and WallachBeth Capital acted as the underwriters for the IPO.

How do I buy shares of Lixte Biotechnology?

Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LIXT

Lixte Biotechnology (LIXT) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free LIXT Stock Alerts

$3.47

+0.17 (+5.15%)

(As of 02:01 PM ET)

Compare

Today's Range: $3.35
▼
$3.53
50-Day Range: $2.09
▼
$3.70
52-Week Range: $1.58
▼
$9.50

Volume: 19,588 shs
Average Volume: 487,316 shs
Market Capitalization: $7.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Lixte Biotechnology alerts:

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Lixte Biotechnology Stock (NASDAQ:LIXT)

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

LIXT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LIXT Stock News Headlines

March 29, 2024 | stockhouse.com

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

March 27, 2024 | theglobeandmail.com

Biotech Steals The Show Following Pre-Clinical Data Announcement

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

March 27, 2024 | msn.com

Lixte stock soars on preclinical data for lead drug LB-100

March 27, 2024 | marketwatch.com

Lixte Biotechnology Shares Rise 51% After Positive Data for LB-100 Cancer Treatment

March 21, 2024 | globenewswire.com

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

February 27, 2024 | globenewswire.com

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

February 26, 2024 | globenewswire.com

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

November 14, 2023 | finanznachrichten.de

Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

November 13, 2023 | finance.yahoo.com

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

November 9, 2023 | morningstar.com

Lixte Biotechnology Holdings Inc LIXT

October 16, 2023 | finance.yahoo.com

LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

September 26, 2023 | finance.yahoo.com

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

August 27, 2023 | wsj.com

Lixte Biotechnology Holdings Inc. Wt

July 20, 2023 | finance.yahoo.com

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

July 18, 2023 | benzinga.com

Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

July 18, 2023 | msn.com

LIXTE Biotechnology falls after company launches $3.5M registered direct offering of shares

July 18, 2023 | marketwatch.com

Lixte Bio Shares Tumble 31% After Pricing $3.5M Stock Offering

July 18, 2023 | finance.yahoo.com

LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

July 17, 2023 | marketwatch.com

Lixte Biotechnology Shares Rise 25% on LB-100 Cancer Treatment Research

July 17, 2023 | msn.com

What's Going On With Lixte Biotechnology (LIXT) Stock?

July 17, 2023 | finance.yahoo.com

Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy

June 23, 2023 | finance.yahoo.com

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

June 7, 2023 | finance.yahoo.com

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

June 5, 2023 | finance.yahoo.com

Owning 53% in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) means that insiders are heavily invested in the company's future

June 2, 2023 | msn.com

LIXTE Biotechnology Holdings announces reverse stock split to obtain minimum price compliance

See More Headlines

Receive LIXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LIXT
CUSIP: N/A
CIK: 1335105
Web: www.lixte.com
Phone: (631) 830-7092
Fax: 631-982-5050
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,090,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -1,202.60%
Return on Assets: -119.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.72
Quick Ratio: 13.72

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.22 per share
Price / Book: 15.00

Miscellaneous

Outstanding Shares: 2,250,000
Free Float: 1,900,000
Market Cap: $7.43 million
Optionable: Not Optionable
Beta: -0.28

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Bastiaan van der Baan M.Sc. (Age 52)
President, CEO & Chairman of the Board of Directors
Comp: $172.78k
Mr. Robert Neal Weingarten (Age 72)
VP & CFO
Comp: $175k
Mr. Eric J. Forman J.D. (Age 45)
VP & COO
Comp: $200k
Dr. James S. Miser M.D. (Age 77)
Chief Medical Officer
Comp: $175k

Key Competitors

View All Competitors

Insiders

Der Baan Bastiaan Jeroen Van
Bought 10,000 shares on 10/3/2023
Total: $28,000.00 ($2.80/share)

View All Insider Transactions

LIXT Stock Analysis - Frequently Asked Questions

How have LIXT shares performed in 2024?: Lixte Biotechnology's stock was trading at $2.35 at the beginning of the year. Since then, LIXT shares have increased by 47.7% and is now trading at $3.47.
View the best growth stocks for 2024 here.
When is Lixte Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our LIXT earnings forecast.
How were Lixte Biotechnology's earnings last quarter?: Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) released its earnings results on Tuesday, March, 19th. The company reported ($0.41) earnings per share for the quarter.
When did Lixte Biotechnology's stock split?: Shares of Lixte Biotechnology reverse split before market open on Monday, June 5th 2023. The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Lixte Biotechnology IPO?: Lixte Biotechnology (LIXT) raised $7 million in an initial public offering (IPO) on Wednesday, November 25th 2020. The company issued 1,500,000 shares at $4.75 per share. WestPark Capital and WallachBeth Capital acted as the underwriters for the IPO.
How do I buy shares of Lixte Biotechnology?: Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LIXT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lixte Biotechnology (LIXT) Stock Price, News & Analysis

About Lixte Biotechnology Stock (NASDAQ:LIXT)

LIXT Stock Price History

LIXT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

LIXT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info